Our findings emphasize that CTGF and NT-proBNP act as complementary biomarkers that reflect myocardial fibrosis, ventricular remodeling, and hemodynamic stress, providing a molecularly and clinically integrated framework for risk prediction. The gene discussed is CCN2; the disease is Myocardial fibrosis.